Co-Diagnostics, Inc. (CODX)
| Market Cap | 205.25M |
| Revenue (ttm) | 74.55M |
| Net Income (ttm) | 42.48M |
| Shares Out | 26.72M |
| EPS (ttm) | 1.52 |
| PE Ratio | 4.71 |
| Forward PE | 10.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $7.16 |
| Previous Close | $7.31 |
| Change ($) | -0.15 |
| Change (%) | -2.05% |
| Day's Open | 7.40 |
| Day's Range | 7.01 - 7.55 |
| Day's Volume | 1,094,746 |
| 52-Week Range | 7.01 - 30.99 |
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 30.00% and 2.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Co-Diagnostics (NASDAQ:CODX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 620.00% year over year to $0.26, which b...
Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the co...
CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, annou...
SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tes...
Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) ...
SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tes...
As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...
Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Austra...
SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced to...
CODX stock rose on the pandemic, but its prospects moving forward look bleak with a sales strategy that is suspect at best. The post If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bai...
Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy...
Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy...
SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, a...
Co-Diagnostics CEO discusses coronavirus testing: We believe robust testing is key to normalizing
coronavirustesting Yahoo Finance's Adam Shapiro and Seana Smith spoke with Co-Diagnostics CEO Dwight Egan about the company's outlook and the latest coronavirus testing methods.
Analysts following this coronavirus stock have darkened their post-pandemic outlook.
The company's recent struggles on the stock market continue.
With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of...
Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnost...
Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnost...
Investors didn't like what they heard in the company's fourth-quarter update.
The company missed earnings expectations and hinted at slowing growth in 2021.
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday that it earned a net income of $42.5 million in 2020 as its Logix Smart coronavirus (COVID-19) test drove record sales. That's a huge turnaround for ...
Shares of Co-Diagnostics (NASDAQ:CODX) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 577.78% year over year to $0.43, which miss...
SALT LAKE CITY, March 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...
CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move. The post Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings ...
SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...
SALT LAKE CITY, March 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d...
2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?
SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d...
SALT LAKE CITY, March 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...
Co-Diagnostics is designing at-home coronavirus PCR saliva test delivering results by smartphone app
Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. ...
Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. ...
Co-Diagnostics Inc (NASDAQ:CODX) has confirmed that its patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health p...
Its technology underpins a coronavirus test that's about to get much wider distribution.
Co-Diagnostics Inc (NASDAQ:CODX) patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer...
With the latter appointment, the company's founder moves into a more advisory role.
Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company's new chief financial officer (CFO). The company said Brown's previous experience includes CFO, vice pres...
SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced tod...
Co-Diagnostics Inc (NASDAQ:CODX) has said it will be presenting on direct saliva testing for coronavirus (COVID-19) at the 28th Annual International Molecular Medicine Tri-Conference, to be held virtual...
These companies have awesome upside potential, and they won't break the bank
The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over.
This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.
SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued...
This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020. The company's Covid-19 tests are differentiated by distinguishing between common cold and...
About CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also pro... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 12, 2017 |
| CEO Dwight Egan | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol CODX |
Analyst Forecasts
According to 3 analysts, the average rating for Co-Diagnostics stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 221.23% from the latest price.